Table 1.
Prognostic factors: present and future (consensus after both rounds).
| Prognostic Factors | YEAR 2020 | TREND 2030 | |||||
|---|---|---|---|---|---|---|---|
| Currently, This Prognostic Factor for PD Is Used… | By 2030, the Use of This Prognostic Factor for PD Will… | ||||||
| Rarely/Never | Often/Always | Consensus | ▼ | = | ▲ | Consensus | |
| Phenotype with axial involvement (blockings and balance problems) | 0% | 100% | Often/Always | 0% | 63% | 37% | Undetermined |
| Cognitive impairment | 1% | 99% | Often/Always | 0% | 59% | 41% | Undetermined |
| Early presence and severity of motor complications | 1% | 99% | Often/Always | 1% | 73% | 26% | Not change |
| Age at onset | 7% | 93% | Often/Always | 0% | 76% | 24% | Not change |
| Neuropsychiatric disorders (depression, apathy, hallucinations) | 8% | 92% | Often/Always | 0% | 48% | 52% | Undetermined |
| Hoehn & Yahr clinical stage | 15% | 85% | Often/Always | 19% | 77% | 5% | Not change |
| Autonomic alterations | 47% | 53% | Undetermined | 3% | 43% | 55% | Undetermined |
| Sleep disorders (RBD associated to PD) | 68% | 32% | Undetermined | 1% | 60% | 39% | Undetermined |
| CSF biomarkers | 97% | 3% | Rarely/Never | 4% | 19% | 77% | Increase ▲ |
| Serum molecular markers (inflammation, neurodegeneration, etc.) | 93% | 7% | Rarely/Never | 1% | 23% | 76% | Increase ▲ |
| Genetic alterations | 91% | 9% | Rarely/Never | 1% | 6% | 93% | Increase ▲ |
| Severe hyposmia or anosmia | 89% | 11% | Rarely/Never | 0% | 87% | 13% | Not change |
| Degree of alteration in DATSCAN and PET studies, among others | 87% | 13% | Rarely/Never | 6% | 45% | 49% | Undetermined |
| Use of structural imaging to determine the degree of alteration (e.g., atrophy in certain areas as predictors of dementia, etc.) | 84% | 16% | Rarely/Never | 5% | 17% | 78% | Increase ▲ |
All panelists (n = 75) answered all questions. The percentage of panelists in each category and consensus after the second round of votes are shown. Bold % indicates that 70% consensus was achieved. CSF: Cerebrospinal fluid. DATSCAN: Dopamine Transporter Scan. PD: Parkinson’s disease. PET: Positron emission tomography. RBD: Rapid eye movement sleep behavior disorder or REM behavior disorder. ▼: it will decrease; =: it will not change; ▲: it will increase.